Navigation Links
MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease

- Numax Achieves Primary Endpoint Among High-Risk Infants Versus Current Standard of Care and Shows Reduction of Medically Attended Outpatient RSV- Related Lower Respiratory Infections -

TORONTO, May 08, 2007 /PRNewswire-FirstCall/ -- MedImmune, Inc. today announced positive results from a large prospective trial conducted for prevention of respiratory syncytial virus (RSV). The trial compared motavizumab, the investigational monoclonal antibody (MAb) also known as Numax(R), with Synagis(R) (palivizumab), the standard of care for preventing RSV hospitalization in high-risk infants. In the Phase 3 study involving 6,635 pre-term infants at high risk for RSV, with a primary endpoint of non- inferiority, motavizumab demonstrated overall 26-percent fewer RSV hospitalizations compared with Synagis (p<0.01 for non-inferiority). Additionally, motavizumab demonstrated a statistically significant 50 percent reduction in the incidence of RSV-specific medically attended outpatient lower respiratory infections (LRIs) (p<0.01) compared with Synagis. These findings were presented today in a poster entitled, Phase 3 Trial of Motavizumab, an Enhanced Potency RSV-Specific MAb for the Prevention of Serious RSV Disease in High-Risk Infants, at the Pediatric Academic Societies' Annual Meeting in Toronto, Canada.

"As RSV continues to be the leading cause of lower respiratory tract infections in infants in the United States, we are very encouraged by the results of this Phase 3 trial, which suggest that motavizumab may help to reduce the chance that our most vulnerable babies will have serious RSV disease," said Edward M. Connor, M.D., chief medical officer and executive vice president. "Data from the study showed that motavizumab was statistically superior to Synagis for the secondary endpoint of outpatient medically attended LRI caused by RSV, and thus may reduce the overall burden of RSV disease compared to the current stan
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
7. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
8. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
9. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:4/1/2015)... 2015  New York College of Health Professions announces ... portfolio with U.S. Patent #8,996,098 donated by its Chairman ... a surgical instrument that allows surgeons to view and ... in the traditional format of a slide that is ... during surgery, thus providing the surgeon real time analysis ...
(Date:4/1/2015)... ASPEN, Colo. , April 1, 2015  Astellas ... (CKF), is pleased to sponsor the second annual Bounce ... award, which will recognize two transplant recipients who exhibit ... a career accomplishment, participation in a sport or hobby, ... loved ones. "The Bounce Back Award ...
(Date:4/1/2015)... 2015  The fairness of the proposed acquisition of ... Pharmaceutical Industries ("Teva") is being investigated by WeissLaw LLP, ... investigation focuses on possible breaches of fiduciary duty and ... of ASPX for agreeing to sell the Company to ... definitive agreement for Teva to acquire ASPX in a ...
Breaking Medicine Technology:Ground-Breaking Surgical Instrument Allows Surgeons to obtain Real Time Biopsies 2Ground-Breaking Surgical Instrument Allows Surgeons to obtain Real Time Biopsies 3Astellas Teams Up with The Chris Klug Foundation on the Bounce Back Award to Recognize Extraordinary Transplant Recipients 2Astellas Teams Up with The Chris Klug Foundation on the Bounce Back Award to Recognize Extraordinary Transplant Recipients 3WeissLaw LLP: Auspex Pharmaceuticals Inc. Acquisition By Teva Pharmaceutical Industries May Not Be In The Best Interest of ASPX Shareholders 2
... Recent Highlights: Qutenza ® (capsaicin) ... adoption by large US institutions; 238 hospitals purchased as of 4Q10, ... Q4 2010 revenue totaled $2.3 million including $0.5 million U.S. Qutenza ... in 17 countries at December 31, 2010 NGX-1998 Phase 2 ...
... March 30, 2011 Rochester Medical Corporation (Nasdaq: ... BioSciences N.V. today approved the previously announced sale of ... subsidiary to Rochester Medical Corporation. Rochester Medical ... and under the terms of the Share Purchase Agreement ...
Cached Medicine Technology:NeurogesX Reports Fourth Quarter and Year-End 2010 Results 2NeurogesX Reports Fourth Quarter and Year-End 2010 Results 3NeurogesX Reports Fourth Quarter and Year-End 2010 Results 4NeurogesX Reports Fourth Quarter and Year-End 2010 Results 5NeurogesX Reports Fourth Quarter and Year-End 2010 Results 6NeurogesX Reports Fourth Quarter and Year-End 2010 Results 7NeurogesX Reports Fourth Quarter and Year-End 2010 Results 8NeurogesX Reports Fourth Quarter and Year-End 2010 Results 9Fornix Shareholders Approve the Sale of Laprolan B.V. to Rochester Medical Corporation 2
(Date:4/1/2015)... (PRWEB) April 01, 2015 Taking an ... National League for Nursing Commission for Nursing Education ... has approved the first NLN CNEA Board of Commissioners. ... FAAN, ANEF, the 15-member board will provide leadership and ... overseeing all accreditation decisions for nursing programs that seek ...
(Date:4/1/2015)... VA (PRWEB) April 01, 2015 ... College of American Pathologists (CAP), the Association for ... Clinical Oncology (ASCO) today released a draft of ... molecular marker testing for patients with primary or ... establish standard molecular marker testing, guide targeted therapies, ...
(Date:4/1/2015)... Dr Roz Kamani, a Vancouver medical aesthetic doctor, ... patients an opportunity to learn more about the latest ... which is an exclusive VIP event conducted three times ... Clinic. It is attended by Dr Roz Kamani’s suppliers ... and services that are on offer. , In ...
(Date:4/1/2015)... 01, 2015 Tempaper has joined forces ... virtual giving campaign that will raise critical funds to ... muscle disease across the United States. , Throughout the ... Tempaperdesigns.com will automatically receive free domestic ground ... and urgently needed progress to children and adults affected ...
(Date:4/1/2015)... 2015 IQ Formulations , one of ... supplement companies in the U.S., today is commending GNC for ... control standards for its herbal supplements.* GNC vowed that its ... ensure the accuracy of labeling on its products. , ... IQ Formulations CEO Jay Cohen said: , “In ...
Breaking Medicine News(10 mins):Health News:NLN Commission for Nursing Education Accreditation (NLN CNEA) Announces Inaugural Commissioners 2Health News:NLN Commission for Nursing Education Accreditation (NLN CNEA) Announces Inaugural Commissioners 3Health News:ASCP, CAP, AMP, and ASCO Issue Draft Colorectal Cancer Molecular Marker Testing Guideline and Announce Opening of Public Comment Period 2Health News:ASCP, CAP, AMP, and ASCO Issue Draft Colorectal Cancer Molecular Marker Testing Guideline and Announce Opening of Public Comment Period 3Health News:ASCP, CAP, AMP, and ASCO Issue Draft Colorectal Cancer Molecular Marker Testing Guideline and Announce Opening of Public Comment Period 4Health News:Dr Roz Kamani Now Offers Patients The Opportunity to Learn About Latest Products and Services 2Health News:Tempaper and MDA Team up in the Fight Against Muscle Disease 2Health News:Tempaper and MDA Team up in the Fight Against Muscle Disease 3Health News:IQ Formulations Applauds GNC for Enhancing Its Testing and Quality Control Processes for Herbal Supplements 2
... common cause of death and disability in children and adolescents, ... a new study by UCLA researchers, the effects of a ... can linger for years. , Reporting in the May ... author and a UCLA post-doctoral fellow, and senior author Robert ...
... Ky., May 13 We,ve all made mistakes: bell bottoms, scrunchies ... in the past. Thanks to advances in skin care and ... In fact, it,s downright dangerous. According to the National Cancer ... in 2009 resulting in about 1,000 deaths. Skin cancer is ...
... was recently recognized by the Art Directors Club ... Awards Exhibition.ScienceFirst graphic designer Michelle Feingold won a ... a speaker training creative platform for a top-tier, ... received Certificates of Excellence. One of the entries ...
... combination medication approved with the extended-release form of ... Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, ... announced that the U.S. Food and Drug Administration ... medication ACTO plus met(R) (pioglitazone HCl and ...
... ,Covering All the Bases® Hitting Challenge, during Major League Baseball,s ,4ALS ... famous ,Luckiest Man, farewell speech as he battled the disease that ... ... (Vocus) May 13, 2009 -- The ALS Association,s is launching the ...
... technology leader in email and file archiving ... and storage management, today announces the release ... Suite with SharePoint Archiving at Microsoft TechEd ... Email & File Archive Enterprise Suite with ...
Cached Medicine News:Health News:UCLA study shows traumatic brain injury haunts children for years 2Health News:Get Sun Smart at the Spa 2Health News:FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes 2Health News:FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes 3Health News:FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes 4Health News:70th Anniversary of Lou Gehrig's Farewell Speech: The ALS Association Launches the 'Covering All the Bases Hitting Challenge' 2Health News:70th Anniversary of Lou Gehrig's Farewell Speech: The ALS Association Launches the 'Covering All the Bases Hitting Challenge' 3Health News:MessageSolution Releases Email & File Archive Enterprise Suite with SharePoint Archiving at Microsoft TechEd North America 2009 2Health News:MessageSolution Releases Email & File Archive Enterprise Suite with SharePoint Archiving at Microsoft TechEd North America 2009 3Health News:MessageSolution Releases Email & File Archive Enterprise Suite with SharePoint Archiving at Microsoft TechEd North America 2009 4Health News:MessageSolution Releases Email & File Archive Enterprise Suite with SharePoint Archiving at Microsoft TechEd North America 2009 5
Headlight module is mounted on UltraLite Plus sweatband....
... rapid rise in intracranial ... intervention and continuous monitoring. ... technology that gets to ... Its versatility makes it ...
... The CODMAN ICP Monitoring ... measurements of intracranial pressure ... or intraventricular levels. The ... rather than through a ...
... The Polaris system delivers the ... cost effective and easy to use, ... level of precision measurement with unprecedented ... both active and passive tools, the ...
Medicine Products: